NICE Recommends Hansa Biopharma’s Idefirix for Certain Kidney Transplants

The UK’s National Institute for Health and Care Excellence (NICE) recommended Hansa Biopharma’s Idefirix (imlifidase) for National Health Service (NHS) use in people who are waiting for a kidney transplant and who are highly sensitized to human leukocyte antigens (HLAs).

High sensitivity to HLAs leads to a greater risk of a kidney transplant being rejected due to the immune system’s response to the surgery. Idefirix would be used as a desensitization treatment option in adult patients.

The recommendation for the enzyme treatment was based on three-year follow-up data that showed the efficacy of Idefirix, NICE said.

The proposed list price for Idefirix is over $167,000 per 11 mg vial, with an average course of treatment expected to cost more than $371,000 at list price. The discounted price for NHS use was not disclosed.